Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

OLAKUNLE O AKINBOBOYE

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1780632844
CMS profile
307931
Location
LAURELTON, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$19,088.32

146 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 3; records 101–146 of 146 matching records. This page contains 46 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

OLAKUNLE O AKINBOBOYE

NPI 1780632844 · CMS profile ID 307931

Allopathic & Osteopathic Physicians / Internal Medicine

LAURELTON, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–146 of 146 matching records. This page contains 46 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1780632844?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
OLAKUNLE O AKINBOBOYE, NPI 1780632844, CMS profile ID 307931. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–146 of 146 matching records. This page contains 46 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1780632844?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). OLAKUNLE O AKINBOBOYE, NPI 1780632844, CMS profile ID 307931. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–146 of 146 matching records. This page contains 46 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1780632844?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
OLAKUNLE O AKINBOBOYE, NPI 1780632844, CMS profile ID 307931, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–146 of 146 matching records. This page contains 46 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1780632844?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

146 matching records · $19,088.32 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 146 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–146 of 146.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Bayer HealthCare Pharmaceuticals Inc. $4.2204/11/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929879385 CMS
Janssen Pharmaceuticals, Inc $32.9304/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886780137 CMS
Novartis Pharmaceuticals Corporation $23.8904/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893490649 CMS
Alnylam Pharmaceuticals Inc. $21.8104/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 926085843 CMS
Merck Sharp & Dohme LLC $22.4903/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944143825 CMS
Novo Nordisk Inc $20.6703/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899395583 CMS
AstraZeneca Pharmaceuticals LP $17.2003/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914853161 CMS
PFIZER INC. $26.0903/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949078211 CMS
Mannkind Corporation $16.6903/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942750345 CMS
Sobi, Inc $1.3103/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940374425 CMS
Sobi, Inc $24.8103/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940374427 CMS
Dexcom, Inc. $24.8603/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957371367 CMS
PFIZER INC. $21.9903/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949076907 CMS
SANOFI-AVENTIS U.S. LLC $19.6703/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938822571 CMS
Novartis Pharmaceuticals Corporation $21.9003/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893490645 CMS
Novartis Pharmaceuticals Corporation $2.9003/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893490651 CMS
Bayer HealthCare Pharmaceuticals Inc. $29.3003/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930029887 CMS
PFIZER INC. $23.2503/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949082111 CMS
PFIZER INC. $2.9503/02/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949654501 CMS
Kowa Pharmaceuticals America, Inc. $20.5703/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 900319429 CMS
Novo Nordisk Inc $22.2602/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898607903 CMS
AstraZeneca Pharmaceuticals LP $21.5702/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915733431 CMS
Janssen Pharmaceuticals, Inc $29.9502/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886780163 CMS
Sobi, Inc $24.2002/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940374423 CMS
Dexcom, Inc. $23.6302/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957371365 CMS
Janssen Pharmaceuticals, Inc $2.5302/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886780133 CMS
SANOFI-AVENTIS U.S. LLC $12.7002/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938822567 CMS
AstraZeneca Pharmaceuticals LP $15.1402/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914699569 CMS
PFIZER INC. $27.8502/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949065601 CMS
Bayer HealthCare Pharmaceuticals Inc. $6.8002/07/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929900515 CMS
Bayer HealthCare Pharmaceuticals Inc. $23.1802/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930121703 CMS
Lilly USA, LLC $16.9702/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918272561 CMS
Novartis Pharmaceuticals Corporation $20.5302/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893490641 CMS
Novo Nordisk Inc $22.0101/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898542121 CMS
Janssen Pharmaceuticals, Inc $16.6601/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886780151 CMS
Novartis Pharmaceuticals Corporation $9.6601/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893490647 CMS
SANOFI-AVENTIS U.S. LLC $19.4701/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938822563 CMS
PFIZER INC. $4,500.0001/21/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949485271 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.0801/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887454153 CMS
Merck Sharp & Dohme LLC $18.5301/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944091625 CMS
PFIZER INC. $3,780.0001/17/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949353115 CMS
AstraZeneca Pharmaceuticals LP $20.0701/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915072379 CMS
Bayer HealthCare Pharmaceuticals Inc. $21.3501/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930182167 CMS
Kowa Pharmaceuticals America, Inc. $16.4301/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 900321011 CMS
Novartis Pharmaceuticals Corporation $2.0201/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893490639 CMS
Mannkind Corporation $20.6201/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942750341 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $13,787.13 154
PY2020 $37,661.38 121
PY2021 $27,784.12 132
PY2022 $19,088.32 146
PY2023 $68,171.74 161
PY2024 $89,269.87 182
PY2025 $126,476.92 210

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $295,126.88 32
PY2024 Principal investigator $338,804.53 48
PY2023 Principal investigator $175,791.70 28
PY2022 Principal investigator $156,765.62 22
PY2021 Principal investigator $62,979.60 41
PY2020 Principal investigator $133,371.59 57
PY2019 Principal investigator $183,159.48 97

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

32 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,000.00 12/01/2025 Non-covered Recipient Entity
Laurelton Heart Specialist PC - MyClinical - PPDS
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215508583
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,500.00 12/01/2025 Non-covered Recipient Entity
Laurelton Heart Specialist PC - MyClinical - PPDS
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215508587
Principal investigator 1 Eidos Therapeutics, Inc. $1,843.20 11/21/2025 Non-covered Recipient Entity
Laurelton Heart Specialist PC
An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants With Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301) No dispute reported 06/30/2026 1250868577
Principal investigator 1 Janssen Research & Development, LLC $4,109.00 11/19/2025 Non-covered Recipient Entity
Laurelton Heart Specialists PC Ultrasound
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175254780
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $8,000.00 11/18/2025 Non-covered Recipient Entity
Queens Heart Institute
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) (AURORA-HFpEF) No dispute reported 06/30/2026 1235994381
Principal investigator 1 Janssen Research & Development, LLC $4,330.00 11/07/2025 Non-covered Recipient Entity
Laurelton Heart Specialists PC Ultrasound
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175254788
Principal investigator 1 Alnylam Pharmaceuticals Inc. $8,500.00 11/05/2025 Non-covered Recipient Entity
Laurelton Heart Specialist PC - MyClinical - PPDS
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215508591
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,000.00 11/05/2025 Non-covered Recipient Entity
Laurelton Heart Specialist PC - MyClinical - PPDS
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215508597
Principal investigator 1 Eidos Therapeutics, Inc. $357.00 10/31/2025 Non-covered Recipient Entity
Laurelton Heart Specialist PC
An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants With Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301) No dispute reported 06/30/2026 1250868579
Principal investigator 1 Ionis Pharmaceuticals, Inc. $634.50 10/02/2025 Non-covered Recipient Entity
LAURELTON HEART SPECIALIST PC
A PHASE 3 GLOBAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ION682884 IN PATIENTS WITH TRANSTHYRETINMEDIATED AMYLOID CARDIOMYOPATHY ATTRCM No dispute reported 06/30/2026 1246787886
Principal investigator 1 Janssen Research & Development, LLC $3,595.00 09/19/2025 Non-covered Recipient Entity
Laurelton Heart Specialists PC Ultrasound
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175254813
Principal investigator 1 Ionis Pharmaceuticals, Inc. $3,179.52 09/01/2025 Non-covered Recipient Entity
LAURELTON HEART SPECIALIST PC
A PHASE 3 GLOBAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ION682884 IN PATIENTS WITH TRANSTHYRETINMEDIATED AMYLOID CARDIOMYOPATHY ATTRCM No dispute reported 06/30/2026 1246787068
Principal investigator 1 Janssen Research & Development, LLC $5,590.00 08/25/2025 Non-covered Recipient Entity
Laurelton Heart Specialists PC Ultrasound
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175254795
Principal investigator 1 Ionis Pharmaceuticals, Inc. $634.50 07/28/2025 Non-covered Recipient Entity
LAURELTON HEART SPECIALIST PC
A PHASE 3 GLOBAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ION682884 IN PATIENTS WITH TRANSTHYRETINMEDIATED AMYLOID CARDIOMYOPATHY ATTRCM No dispute reported 06/30/2026 1246785782
Principal investigator 1 Janssen Research & Development, LLC $1,674.00 07/23/2025 Non-covered Recipient Entity
Laurelton Heart Specialists PC Ultrasound
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175254772
Principal investigator 1 Eidos Therapeutics, Inc. $1,150.00 07/22/2025 Non-covered Recipient Entity
Laurelton Heart Specialist PC
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial) No dispute reported 06/30/2026 1250868581
Principal investigator 1 Eidos Therapeutics, Inc. $10,515.00 07/22/2025 Non-covered Recipient Entity
Laurelton Heart Specialist PC
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial) No dispute reported 06/30/2026 1250868583
Principal investigator 1 Exact Sciences Corporation $32.50 07/02/2025 Non-covered Recipient Entity
MYCLINICAL LLC
Informed Choice Intervention for Colorectal Cancer Screening: COMPASS No dispute reported 06/30/2026 1244037068
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,524.41 06/24/2025 Non-covered Recipient Entity
Queens Heart Institute
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) (AURORA-HFpEF) No dispute reported 06/30/2026 1235994379
Principal investigator 1 Janssen Research & Development, LLC $1,219.00 06/23/2025 Non-covered Recipient Entity
Laurelton Heart Specialists PC Ultrasound
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175254763
Principal investigator 1 Ionis Pharmaceuticals, Inc. $2,053.08 06/20/2025 Non-covered Recipient Entity
LAURELTON HEART SPECIALIST PC
A PHASE 3 GLOBAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ION682884 IN PATIENTS WITH TRANSTHYRETINMEDIATED AMYLOID CARDIOMYOPATHY ATTRCM No dispute reported 06/30/2026 1246784464
Principal investigator 1 Janssen Research & Development, LLC $55,406.00 06/20/2025 Non-covered Recipient Entity
Laurelton Heart Specialists PC Ultrasound
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175254821
Principal investigator 1 AstraZeneca Pharmaceuticals LP $33,051.70 05/02/2025 Non-covered Recipient Entity
LAURELTON HEART SPECIALIST, P.C
A Randomised,Double Blind,Placebo Controlled,Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with Resistant Hypertension No dispute reported 06/30/2026 1185544779
Principal investigator 1 PFIZER INC. $1,210.50 04/26/2025 Non-covered Recipient Entity
Laurelton Heart Specialist PC
A LOWINTERVENTIONAL PROSPECTIVE LONGITUDINAL COHORT STUDY TO COLLECT DIGITAL FUNCTIONAL ASSESSMENTS AND EVALUATE SYMPTOMS IN STUDY PARTICIPANTS WITH CHRONIC HEART FAILURE No dispute reported 06/30/2026 1228795013
Principal investigator 1 Novartis Pharmaceuticals Corporation $12,650.00 04/03/2025 Non-covered Recipient Entity
LAURELTON HEART SPECIALIST PC
A randomized, controlled, multicenter, open-label trial comparing a post-discharge care pathway involving aggressive LDL-C management with inclisiran with usual care in patients with a recent acute coronary syndrome No dispute reported 06/30/2026 1190308308
Principal investigator 1 AstraZeneca UK Limited $78,229.60 03/25/2025 Non-covered Recipient Entity
LAURELTON HEART SPECIALIST, P.C
A Phase IIb Two cohort Randomised Placebo controlled Double blind Multicentre Dose ranging Study of AZD5462 in Stable Patients with Chronic Heart Failure No dispute reported 06/30/2026 1185544781
Principal investigator 1 PFIZER INC. $12,000.00 03/04/2025 Non-covered Recipient Entity
Laurelton Heart Specialist PC
A LOWINTERVENTIONAL PROSPECTIVE LONGITUDINAL COHORT STUDY TO COLLECT DIGITAL FUNCTIONAL ASSESSMENTS AND EVALUATE SYMPTOMS IN STUDY PARTICIPANTS WITH CHRONIC HEART FAILURE No dispute reported 06/30/2026 1228794694
Principal investigator 1 Exact Sciences Corporation $149.50 02/28/2025 Non-covered Recipient Entity
MYCLINICAL LLC
Informed Choice Intervention for Colorectal Cancer Screening: COMPASS No dispute reported 06/30/2026 1244037063
Principal investigator 1 PFIZER INC. $3,062.24 02/28/2025 Non-covered Recipient Entity
Laurelton Heart Specialist PC
A LOWINTERVENTIONAL PROSPECTIVE LONGITUDINAL COHORT STUDY TO COLLECT DIGITAL FUNCTIONAL ASSESSMENTS AND EVALUATE SYMPTOMS IN STUDY PARTICIPANTS WITH CHRONIC HEART FAILURE No dispute reported 06/30/2026 1228759029
Principal investigator 1 AstraZeneca Pharmaceuticals LP $10,557.93 01/22/2025 Non-covered Recipient Entity
QUEENS HEART INSTITUTE
This is a randomised double blind placebo controlled multi center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with left ventricular ejection fractio No dispute reported 06/30/2026 1185544777
Principal investigator 1 Janssen Research & Development, LLC $1,527.00 01/22/2025 Non-covered Recipient Entity
Laurelton Heart Specialists PC Ultrasound
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175254805
Principal investigator 1 AstraZeneca Pharmaceuticals LP $19,841.70 01/17/2025 Non-covered Recipient Entity
QUEENS HEART INSTITUTE
A Randomised,Double Blind,Placebo Controlled,Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with Resistant Hypertension No dispute reported 06/30/2026 1185544775

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2025 Amount invested $106,246.57 1
PY2025 Value of interest $131,167.50 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

1 record · PY2025

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2025 VivaQuant Inc, dba Rhythm Express $106,246.57 $131,167.50 Common stock (certificated), 34,978 shares acquired on Nov 11, 2021 at $3.0375 per share; current price per share $3.75 Physician Covered Recipient No dispute reported 06/30/2026 1250896541